WuXi Biologics (Cayman) Inc. (BKK:WUXI06)

Market Cap	589.55B +48.1%
Revenue (ttm)	98.25B +16.7%
Net Income	22.13B +46.3%
EPS	5.23 +47.9%
Shares Out	n/a
PE Ratio	26.64
Forward PE	19.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,505
Open	3.600
Previous Close	3.440
Day's Range	3.600 - 3.620
52-Week Range	3.160 - 4.280
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 24, 2026

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and ...

• Industry: Commercial Physical and Biological Research
• Founded: 2014
• Employees: 13,252
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: WUXI06

Financial Performance

In 2025, WuXi Biologics's revenue was 21.79 billion, an increase of 16.68% compared to the previous year's 18.68 billion. Earnings were 4.91 billion, an increase of 46.25%.

Financial numbers in CNY